European Commission Grants BioVentrix CE Mark Extension for Revivent TC Less Invasive Ventricular Enhancement Therapy
SAN RAMON, Calif. – January 22, 2020 – BioVentrix, Inc., [...]
BioVentrix Announces Publication of Positive One-Year Outcomes for Revivent TC System
Study Published in European Journal of Heart Failure Shows Significant [...]
FDA Grants Breakthrough Device Designation Status for BioVentrix Revivent TC Transcatheter Ventricular Enhancement System for Heart Failure
San Ramon, CA, Nov. 19, 2019 -- BioVentrix, Inc., a [...]
BioVentrix Enrolls and Treats First Patient in REVIVE-HF European RCT for Ischemic Heart Failure Patients
San Ramon, CA, USA – Oct. 07, 2019 – BioVentrix, [...]
BioVentrix Announces Study Design for REVIVE-HF: Randomized Controlled Trial (RCT) in Europe
To demonstrate that treatment with the Revivent TCTM System is [...]
BioVentrix Announces the Appointment of Pedro Marques as VP of Sales in Europe
He will be focused on growth of the Revivent TCTM [...]
BioVentrix Announces Key Additions to Leadership Team
Chief Medical Officer for Europe and Chief Financial Officer named [...]
BioVentrix Achieves 2019 NUB Reimbursement Status 1 in Germany for Revivent TC™ TransCatheter Ventricular Enhancement System
San Ramon, Calif., February 28, 2019 — BioVentrix, Inc. a [...]
BioVentrix Announces First Patient at Cardiovascular Institute of the South Successfully Treated in IDE Study of Revivent TC™ TransCatheter Ventricular Enhancement Treatment
San Ramon, Calif., and Houma, LA,, March 12, 2018 — [...]
BioVentrix Achieves 2018 NUB Reimbursement Status 1 in Germany for Revivent TC™ TransCatheter Ventricular Enhancement System
San Ramon, Calif., February 06, 2018 — BioVentrix, Inc. a [...]
